Natalizumab is associated with no evidence of disease activity and with improvement in disability and cognitive performance in anti-JC virus seronegative patients with early relapsing-remitting multiple sclerosis: STRIVE 4-year results
MULTIPLE SCLEROSIS JOURNAL（2019）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined